Compare iShares MSCI India ETF (INDA) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Twist Bioscience Corp — how do they compare? iShares MSCI India ETF trades at $46.03 (market cap $5.73B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 58 Days and Twist Bioscience Corp for 27 Days on average.
| INDA | TWST | |
|---|---|---|
Market Cap | $5.73B | $10.08B |
Volume | 6,797,522 | 4,229,037 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $205.00 |
52-Week Low | $45.42 | $25.45 |
Typical Hold Time | 58 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $45.56, down 1.21% with bearish technical signals dominating. The ETF faces headwinds from India's economic challenges including coal power shortages, below-average monsoon rains, and IT sector weakness. Technical indicators show oversold conditions with RSI readings below 20, while moving averages signal strong bearish momentum. Recent news highlights energy security concerns and pharmaceutical export challenges affecting the underlying Indian market exposure.
The outlook remains cautious given multiple sector-specific pressures in India. Investment opportunity exists for long-term investors betting on India's growth story at depressed levels, but risks include persistent energy shortages, agricultural output concerns, and global trade tensions that could further pressure the ETF's performance in the near term.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
